Answer Questions about Andexxa, the New Apixaban and Rivaroxaban Reversal Agent

July 2018

You'll hear about Andexxa (an-DEK-sah, inactivated recombinant factor Xa), the new, IV direct oral anticoagulant (DOAC) reversal agent.

Andexxa binds and inactivates factor Xa inhibitors...compared to idarucizumab (Praxbind), which reverses dabigatran (Pradaxa).

Andexxa's FDA approval is based on quick reversal of clotting time in patients taking apixaban and rivaroxaban. But it's also being studied with other anticoagulants...betrixaban (Bevyxxa), edoxaban (Savaysa), and enoxaparin.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote